Skip to main content

TableĀ 3 Upcoming cardiovascular outcomes trials in type 2 diabetes

From: Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes

Study

Drug

Comparator

Primary endpoint

Results

CANVAS

Canagliflozin

Placebo

Major adverse cardiovascular events, including CV death, non-fatal MI, and non-fatal stroke

2017

CARMELINA

Linagliptin

Placebo

Composite endpoint: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalization for unstable angina pectoris

2018

EXSCEL

Exenatide once weekly

Placebo

Composite endpoint: cardiovascular death, non-fatal MI, or non-fatal stroke

2018

REWIND

Dulaglutide

Placebo

Composite endpoint: cardiovascular death, non-fatal MI, or non-fatal stroke

2018

DECLARE-TIMI 58

Dapagliflozin

Placebo

Composite endpoint: CV death, MI or ischemic stroke

2019

CAROLINA

Linagliptin

Glimepiride

Composite endpoint: CV death, non-fatal MI (excluding silent MI), non-fatal stroke and hospitalisation for unstable angina pectoris

2019

  1. CV cardiovascular, MI myocardial infarction